Aligos Therapeutics Past Earnings Performance
Past criteria checks 0/6
Aligos Therapeutics's earnings have been declining at an average annual rate of -10.4%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 68.3% per year.
Key information
-10.4%
Earnings growth rate
59.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 68.3% |
| Return on equity | -95.2% |
| Net Margin | -564.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Apr 09
Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Share Price Is Matching Sentiment Around Its Revenues
Feb 23Here's Why We're Watching Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation
Oct 24We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully
Jul 17We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully
Mar 11Aligos Therapeutics begins 12-week dosing in phase 1b study to treat hepatitis B
Jul 25We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate
Jul 11We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate
Feb 02Here's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation
Oct 19Aligos Therapeutics EPS beats by $0.16
May 10We're Hopeful That Aligos Therapeutics (NASDAQ:ALGS) Will Use Its Cash Wisely
May 01What Is The Ownership Structure Like For Aligos Therapeutics, Inc. (NASDAQ:ALGS)?
Jan 16Dosing underway for Aligos Therapeutics' hepatitis B candidate in early-stage study
Oct 30Revenue & Expenses BreakdownBeta
How Aligos Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 16 | -88 | 30 | 0 |
| 30 Sep 23 | 16 | -82 | 31 | 0 |
| 30 Jun 23 | 17 | -82 | 30 | 0 |
| 31 Mar 23 | 14 | -83 | 28 | 0 |
| 31 Dec 22 | 14 | -96 | 26 | 0 |
| 30 Sep 22 | 11 | -112 | 29 | 0 |
| 30 Jun 22 | 8 | -126 | 30 | 0 |
| 31 Mar 22 | 6 | -136 | 29 | 0 |
| 31 Dec 21 | 4 | -128 | 29 | 0 |
| 30 Sep 21 | 4 | -125 | 25 | 0 |
| 30 Jun 21 | 2 | -125 | 23 | 0 |
| 31 Mar 21 | 1 | -116 | 20 | 0 |
| 31 Dec 20 | 0 | -109 | 18 | 0 |
| 30 Sep 20 | 0 | -92 | 15 | 15 |
| 30 Jun 20 | 0 | -73 | 14 | 27 |
| 31 Mar 20 | 0 | -62 | 12 | 35 |
| 31 Dec 19 | 0 | -52 | 10 | 44 |
Quality Earnings: ALGS is currently unprofitable.
Growing Profit Margin: ALGS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALGS is unprofitable, and losses have increased over the past 5 years at a rate of 10.4% per year.
Accelerating Growth: Unable to compare ALGS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALGS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: ALGS has a negative Return on Equity (-95.22%), as it is currently unprofitable.